Alwin Schuller

Alwin Schuller

Company: AstraZeneca

Job title: Senior Principal Scientist


Alwin has ~20 years’ industry experience mentoring diverse research teams and providing biology and in vivo pharmacology strategy to various small molecule and antibody projects ranging from target validation through clinical development. The past ~7 years he has held various roles at AstraZeneca including bioscience lead of the Arginase program (from inception to candidate selection), the A2AR inhibitor AZD4635, and the MET inhibitor AZD6094 / savolitinib. 


Discussion/Q&A 2:30 pm

Read more

day: Day One

AZD0011 Shows Immune Activation & Anti-Tumor Activity as Mono- & Combination Therapy in Syngeneic Tumor Models 1:30 pm

Developed a novel arginase inhibitor (AZD0011) able to reverse arginase induced immune suppression in vivo Inhibition of arginase by AZD0011 increases the number and activation of intra-tumoral cytotoxic T-cells and NK cells Arginase inhibitor AZD0011 shows combination activity with various immune-activating strategies including checkpoint inhibitors and TLR agonistsRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.